ACSL5 functions as an immune-dependent tumor suppressor, enhancing tumor sensitivity to programmed cell death protein 1 (PD-1) blockade therapy and promoting CD8+ T cell-mediated cytotoxicity in vivo and in vitro through regulation of major histocompatibility complex class I (MHC-I)-mediated antigen presentation [65]. The gene discussed is CD8A; the disease is neoplasm.